• Reovirus serotype 3-dearing strain, a double-stranded replication-competent RNA nonenveloped icosahedral virus
    • Currently in phase 1/2 clinical trials for colorectal cancer, NSCLC, castration-resistant prostate cancer, breast cancer, and pancreatic cancer
    • Recommended dose: 3 × 1010 tissue culture effective dose (TCID50) well tolerated
    • Common side effects: Fever, chills, myalgias, cold-like symptoms, GI upset, fatigue
    (Gollamudi et al., 2010)
    Other topics in Targeted and Immunotherapy Agents